Cover Image

A combination therapy of ingredients from TCM for the prevention and treatment of gastric cancer by targeting HER2/ PD-L1

Gastric cancer (GC) is a globally important disease. Targeted therapies licensed to treat gastric cancer include trastuzumab, which targets HER2, and nivolumab or pembrolizumab, which block PD-1/PD-L1. The main challenge of tumor molecule-targeted drugs is resistance. Based on the multicomponent and...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ling Li (Author), Jia-wei Li (Author), Xiao-jie Jin (Author), Cheng-hao Li (Author), Jun-jie Li (Author), Ming Fang (Author), Lu Qiu (Author), Si-yu Wang (Author), Wei Chu (Author), Yong-qi Liu (Author)
Format:	Book
Published:	Elsevier, 2021-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Hsp90 up-regulates PD-L1 to promote HPV-positive cervical cancer via HER2/PI3K/AKT pathway
by: Jie Zeng, et al.
Published: (2021)

The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
by: Li Chen, et al.
Published: (2022)

AGREE II for TCM: Tailored to evaluate methodological quality of TCM clinical practice guidelines
by: Xiuli Xie, et al.
Published: (2023)

Machine learning in TCM with natural products and molecules: current status and future perspectives
by: Suya Ma, et al.
Published: (2023)

Insights on the development of TCM nursing
by: Jun-Qiang Zhao, et al.
Published: (2016)

Validity and reliability of the evaluation tool of TCM confidence in students with TCM learning experience
by: Jia Rui-Min, et al.
Published: (2023)

Therapeutic effects on cancer of the active ingredients in rhizoma paridis
by: Jie Li, et al.
Published: (2023)

Study on the comprehensive evaluation of TCM service capacity in 71 county-level TCM hospitals of Zhejiang Province in China
by: Xuehui Meng, et al.
Published: (2024)

Application of morbid animal model in drug safety evaluation of TCM
by: Ning eKe-Yong, et al.
Published: (2015)

Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes
by: Li Chen, et al.
Published: (2022)

Corrigendum: Controlling nutritional status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1) outcomes
by: Li Chen, et al.
Published: (2022)

Constitution Identification System for Traditional Chinese Medicine (TCM) Based on Correlation Between TCM Constitution and Physical Examination Indices
by: Yue Luo, et al.
Published: (2018)

Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes
by: Song Cang, et al.
Published: (2021)

From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer
by: Sun J, et al.
Published: (2022)

A Comprehensive Evaluation of China's TCM Medical Service System: An Empirical Research by Integrated Factor Analysis and TOPSIS
by: Zhi-Guang Li, et al.
Published: (2020)

Differences in medical costs between TCM users and TCM nonusers in inpatients with thalassemia
by: Zhaoran Han, et al.
Published: (2023)

Vitexicarpin inhibits overexpression of GNAO1 and plays a role in gastric cancer cell proliferation and apoptosis
by: Si-Ping Wang, et al.
Published: (2015)

TCM targets ferroptosis: potential treatments for cancer
by: Liwen Qin, et al.
Published: (2024)

TCM Fingerprint database: A digital approach to scientifically reflect the internal quality of traditional Chinese medicine
by: Qin Wang, et al.
Published: (2023)

From Research on TCM Images to Historiography of TCM Images-Comments on History of Chinese Image Culture: Medical Image Volume
by: Ran WEI, et al.
Published: (2024)

The bone-protective mechanisms of active components from TCM drugs in rheumatoid arthritis treatment
by: Qingyi Lu, et al.
Published: (2022)

From non-targeted to targeted GC-MS metabolomics strategy for identification of TCM preparations containing natural and artificial musk
by: Meng Ding, et al.
Published: (2022)

Analysis and thinking of the COVID-19 infection TCM intervention plan
by: Siming Tao, et al.
Published: (2020)

The addition of PD-1 inhibitor overcame trastuzumab resistance in patients with HER2 positive, PD-L1 negative metastatic gastric cancer: Case report and review of literature
by: Zhenpeng Wen, et al.
Published: (2024)

Study on the synergistic development of TCM service trade within the GBA
by: Qiu Zhang, et al.
Published: (2023)

Professionalism in traditional Chinese medicine (TCM) practitioners: a qualitative study
by: Yu Heng Kwan, et al.
Published: (2020)

Peptidomimetic-based antibody surrogate for HER2
by: Mengmeng Zheng, et al.
Published: (2021)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
by: Shun-Long Ou, et al.
Published: (2023)

High-throughput transcriptional profiling of perturbations by Panax ginseng saponins and Panax notoginseng saponins using TCM-seq
by: Junyun Cheng, et al.
Published: (2023)

Global incidence and mortality trends of gastric cancer and predicted mortality of gastric cancer by 2035
by: Ju-Li Lin, et al.
Published: (2024)

The Anticancer Properties of Tanshinones and the Pharmacological Effects of Their Active Ingredients
by: Li Fu, et al.
Published: (2020)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
by: Jian-ye Zhang, et al.
Published: (2020)

Pyrrolizidine alkaloids and health risk of three Boraginaceae used in TCM
by: Ke Zan, et al.
Published: (2023)

HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
by: Weiling Li, et al.
Published: (2022)

Identification of a Pharmacological Biomarker for the Bioassay-Based Quality Control of a Thirteen-Component TCM Formula (Lianhua Qingwen) Used in Treating Influenza A Virus (H1N1) Infection
by: Dan Gao, et al.
Published: (2020)

Application of Neural Network and Cluster Analyses to Differentiate TCM Patterns in Patients With Breast Cancer
by: Wei-Te Huang, et al.
Published: (2020)

The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China
by: Lu Li, et al.
Published: (2024)

Multicomponent self-assembly based on bioactive molecules of traditional Chinese medicine (TCM)
by: Liangchun Li, et al.
Published: (2022)

Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China
by: Lu Li, et al.
Published: (2024)

Bioactive Ingredients in Chinese Herbal Medicines That Target Non-coding RNAs: Promising New Choices for Disease Treatment
by: Yan Dong, et al.
Published: (2019)